BriaCell Therapeutics announced that its Bria-IMT cell therapy, plus an immune checkpoint inhibitor regimen, achieved ...
A phase 2/3 non-inferiority study compared de-escalation strategies to standard chemoradiation in patients with human ...
MedPage Today on MSN19h
Colorectal Cancer Screening Uptake Tripled in 45-49 Age GroupMean rates of colorectal cancer (CRC) screening tripled among average-risk individuals 45-49 years old after the U.S.
WARN notices filed with the state show more job cuts due in the health sector as companies look to cut costs and streamline ...
The cuts follow an ongoing wave of staff reductions at big drug companies. Pharma giants have terminated thousands of ...
Bristol Myers' immunotherapy can now be used before and after surgery in the U.S. Elsewhere, J&J, Bayer, Bristol Myers Squibb and Pfizer are trimming staff.
The approval came days before the FDA’s expected deadline and makes this the only PD-1 inhibitor approved for resectable ...
Bristol Myers Squibb (BMS) has received approval from the US Food and Drug Administration (FDA) for Opdivo to treat adults ...
Having already been on a winding journey, Enjaymo, which Sanofi acquired through a 2018 buyout of Bioverativ, is now headed ...
On Wednesday, Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $53.76 which represents a slight increase of $0.86 or 1.63% from the prior close of $52.9. The stock opened at ...
In 2023, BMS received a similar approval across the pond. The National Institute for Health and Care Excellence (NICE) cleared Opdivo (nivolumab) for use with platinum-based chemo to reduce the size ...
BeiGene has officially launched its PD-1 cancer drug Tevimbra in the U.S. more than six months after receiving a much-delayed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback